Top Markets
#1 Akedo Akedo +73.71%
#2 Glidr Glidr +51.75%
#3 DOVU DOVU +48.71%
#4 Cross Cross +43.52%
#5 Black Phoenix Black Phoenix +33.78%
#6 Cap Cap +25.61%
#7 Velvet Velvet +25.32%
#8 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +19.62%
#9 DoubleZero DoubleZero +12.53%
#10 Humanity Humanity +10.30%
Coin of the day
Akedo Akedo
Instellingen
Taal
DUTCH
Valuta
USD
Thema
Lipidor AB (publ) Lipidor AB (publ)

Lipidor AB (publ)

LIPI
Rang in aandelen #39101
Lipidor AB (publ), a Swedish pharmaceutical company founded in Danderyd in... Lipidor AB (publ), a Swedish pharmaceutical company founded in Danderyd in 2009, specializes in developing medicinal products. Its core business centers on creating treatments for various skin conditions, including psoriasis, bacterial skin infections, and atopic dermatitis. The company's product pipeline includes AKP-01, which is currently in Phase III clinical trials for psoriasis, while other formulations like AKP-02 (also for psoriasis) and AKP-03 and AKP-07 (for eczema) are in earlier, preclinical development stages. Beyond its own drug candidates, Lipidor manufactures and supplies active pharmaceutical ingredients (APIs). These APIs are incorporated into products addressing a broad spectrum of therapeutic applications, such as managing psoriasis, microbial infections, inflammation, fungal issues, local pain relief, acne, wound healing, eczema, and migraines. Lipidor also caters to the animal health market, offering a line of spray-on skin care products for dogs, cats, and horses. Additionally, it develops consumer health items designed for purposes like antibacterial action, antiseptic care, moisturizing, disinfection, and treating acne and warts. In a key strategic alliance, Lipidor has partnered with Cannassure Therapeutics Ltd. This collaboration aims to advance topical medicinal cannabis products specifically formulated to alleviate skin inflammations and psoriatic lesions.
Aandeelprijs
$0.02243487
Laatst gesynchroniseerd: 2025-06-04
Marktkapitalisatie
$650.09K
Verandering (1 dag)
0.39%
Verandering (1 jaar)
0.00%
Land
SE
Handel Lipidor AB (publ) (LIPI)

Categorie

Healthcare
P/S-ratio voor Lipidor AB (publ) (LIPI)
P/S-ratio op August 2026 TTM: 12.49K
Volgens de meest recente financiële rapporten en aandelenkoers van Lipidor AB (publ) is de huidige P/S-ratio (TTM) 12.49K. Eind 2023 had het bedrijf een P/S-ratio van 187.24.
P/S-ratiohistoriek voor Lipidor AB (publ) van 2016 tot 2026
P/S-ratio aan het einde van elk jaar
Jaar P/S-ratio Wijzigen
2026 (TTM) 12.49K 89.82%
2024 6.58K 3,414.61%
2023 187.24 -60.49%
2022 473.93 2,985.50%
2021 15.36 -97.13%
2020 534.79 -88.42%
2019 4.62K 822.07%
2018 501.03 35.80%
2017 368.94 -14.60%
2016 432.02 0.00%
P/S-ratio voor vergelijkbare bedrijven of concurrenten
Bedrijf P/S-ratio Verschil in P/S-ratio Land
Eli Lilly and Company Eli Lilly and Company
Eli Lilly and Company
LLY.US
14.97 -99.88%
US
Johnson & Johnson Johnson & Johnson
Johnson & Johnson
JNJ.US
6.31 -99.95%
US
AbbVie Inc. AbbVie Inc.
AbbVie Inc.
ABBV.US
7.06 -99.94%
US
Roche Holding AG Roche Holding AG
Roche Holding AG
RO.SW
4.66 -99.96%
CH
Merck & Co., Inc. Merck & Co., Inc.
Merck & Co., Inc.
MRK.US
4.90 -99.96%
US